Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [11C]RO6924963
RO6924963 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: Tracer Selection | EXPERIMENTAL | Participants will receive a single dose of one tracer on one occasion and a single dose of a different tracer after 7 to 14 days and will be followed for 7 to 14 days for safety. At the end of Part 1, one tracer with the best performance will be selected for further study in Part 2. |
| Part 2A: Test-Retest | EXPERIMENTAL | Participants will receive a single dose of selected tracer from Part 1 on one occasion and then same tracer will be administered after 6 weeks. Participants will be followed for 7 to 14 days after last PET tracer administration for safety. |
| Part 2B: Dosimetry | EXPERIMENTAL | Participants will receive a single dose of selected tracer from Part 1 and will be followed for 7 to 14 days for evaluation of radiation dosimetry. |
| Name | Type | Description |
|---|---|---|
| [11C]RO6924963 | DRUG | Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[11C\]RO6924963 injected will be \</=10 micrograms (mcg), injection volume \</=20 milliliters (mL). Target injected activity for \[11C\]RO6924963 will be 370-740 megabecquerel (MBq) \[10-20 millicurie (mCi)\]. |
| [11C]RO6931643 | DRUG | Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[11C\]RO6931643 injected will be \</=10 mcg, injection volume \</=20 mL. Target injected activity for \[11C\]RO6931643 will be 370-740 MBq (10-20 mCi). |
| [18F]RO6958948 | DRUG | Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[18F\]RO6958948 injected will be \</=10 mcg, injection volume \</=20 mL. Target injected activity for \[18F\]RO6958948 will be 185-370 MBq (5-10 mCi). The final activity of \[18F\] RO6958948 will be adjusted up to 10 mCi per scan to allow sufficient counts by end of 200 minutes post radiotracer injection. |
Inclusion Criteria: Inclusion Criteria for All Participants * Agreement to use highly effective contraception measures * If participants are on any concomitant medication, the indication and dosage of these medicines should be stable for at least 4 weeks prior to study start with the expectation t...
Top 20 of 30 competitors
RO6924963 is an investigational small molecule developed by Roche Holding AG as a positron emission tomography (PET) imaging tracer for tau protein in the brain. It was studied in Alzheimer's disease and healthy volunteers to evaluate its use as a tau imaging agent.
RO6924963 is being evaluated as a PET imaging tracer for detecting and measuring tau protein in the brains of people with Alzheimer's disease. It is intended as a diagnostic imaging tool rather than a therapeutic treatment for the disease.
RO6924963 is developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the clinical research evaluating this compound as a tau PET imaging tracer.
RO6924963 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The single Phase 1 trial evaluating it has been completed.
RO6924963 was evaluated in one completed Phase 1 trial, NCT02187627, titled Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for PET Imaging of Tau in Healthy and Alzheimer's Disease Participants. The trial enrolled 52 participants in the United States.
Yes, [11C]RO6924963 is another name for RO6924963. The [11C] prefix refers to the carbon-11 radiolabel used in the compound, which allows it to be detected during positron emission tomography imaging.